TY  - JOUR
AU  - Perez, Marco
AU  - Lucena-Cacace, Antonio
AU  - Miguel Marin-Gomez, Luis
AU  - Padillo-Ruiz, Javier
AU  - Jose Robles-Frias, Maria
AU  - Saez, Carmen
AU  - Garcia-Carbonero, Rocio
AU  - Carnero, Amancio
PY  - 2016
DO  - 10.18632/oncotarget.8880
UR  - http://hdl.handle.net/10668/19427
T2  - Oncotarget
AB  - Despite the development of new antineoplastic agents for the treatment of colorectal cancer (CRC), oxaliplatin and fluoropyrimidines remain the most commonly employed drugs for the treatment of both early and advanced disease. Intrinsic or acquired...
LA  - en
PB  - Impact journals llc
KW  - metastatic colorectal carcinoma
KW  - cancer treatment
KW  - biomarkers
KW  - Src kinase
KW  - pdx models
KW  - Human-colon-carcinoma
KW  - Cancer cell-lines
KW  - Tyrosine kinase
KW  - Family kinases
KW  - Therapeutic implications
KW  - Down-regulation
KW  - Breast-cancer
KW  - Solid tumors
KW  - C-src
KW  - Resistance
TI  - Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src
TY  - research article
VL  - 7
ER  -